Pharmacology of agents used in bone marrow transplant conditioning regimens.
about
High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoNosocomial epiglottitis associated with penicillin- and cephalosporin-resistant Streptococcus pneumoniae bacteremia.High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions.Primary central nervous system lymphoma: essential points in diagnosis and management.Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.Current and emerging pharmacotherapies for primary CNS lymphoma.High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.Inducible disruption of the c-myb gene allows allogeneic bone marrow transplantation without irradiation.
P2860
Q33626490-20312315-83B6-4642-BB75-E355F988AA10Q34443622-10A321A9-09B1-4795-AA48-7772BBBA7494Q34943963-DF87C690-3044-4691-B774-D139FAF47A91Q37070605-05BD398E-F957-44F3-8848-C00739E57CB6Q37330176-6C359E56-434A-47D0-91EB-4B8EAE32DAFBQ39185721-0B3E798D-F9E4-4E2A-802E-F27D0D2EE2CAQ41276228-02B9F8EB-4263-4272-9884-A70560769344Q42126754-05E2289C-4554-4DA0-A1AA-957831168B10Q44401515-700D37A0-038F-47DD-A69E-2CCD8D32AAE2Q48017244-164707A0-6A5A-4C88-A716-3B47088AAFEEQ48704224-3CA36D32-0E48-4F10-852B-E72E35D3E0BFQ48823168-36038464-17BC-47BE-B42B-99F9C78E7780Q52690901-20C5A0DF-2ED8-4345-9871-BECD0D56CD09
P2860
Pharmacology of agents used in bone marrow transplant conditioning regimens.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@ast
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@en
type
label
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@ast
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@en
prefLabel
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@ast
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@en
P2093
P1476
Pharmacology of agents used in bone marrow transplant conditioning regimens.
@en
P2093
DeGregorio MW
Rappeport JM
P304
P356
10.1016/1040-8428(92)90092-5
P577
1992-11-01T00:00:00Z